In the long term, last week's drug patent ruling and other intellectual property developments in India will put patients there at risk of not gaining access to the newest life-saving drugs, PhRMA CEO John J. Castellani writes in this blog post. "Our industry recognizes the challenges the Indian Government faces in extending healthcare to a vast population," Castellani writes. "Still, we cannot sacrifice existing and future innovations that many patients rely on and that will be critical to meeting the unmet medical needs of the future."

Full Story:

Related Summaries